Non-profit organization

CURRICULUM VITAE - Prof. Vladimír Frecer

Position: Scientific Director ICARST n.o.

Affiliation, Address: Faculty of Pharmacy, Comenius University, Odbojarov 10, Bratislava 83232, Slovakia

Education (degrees, universities, dates)

2021 Prof., Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia

2015 Assoc. Prof., Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia 

2012 DSc., Biophysics, Comenius University, Bratislava, Slovakia 

1989 PhD. Faculty of Chemical and Food Technology, Slovak Technical University, Bratislava, Slovakia 

1981 MSc. Faculty of Chemical and Food Technology, Slovak Technical University, Bratislava, Slovakia

Career, Employment (employers, positions, dates)

2021 - present Full Professor, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia

2015 - 2020 Assoc. Professor, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia

2011 - present Scientific Director, ICARST n.o., Bratislava, Slovakia

2010 - 2015 Assist. Professor, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia 

1983 - 2010 Slovak Academy of Science, Cancer Research Institute, Researcher

Visiting Professor

2000 - 2009 International Centre for Science and High Technology, UNIDO, AREA Science Park, Trieste, Italy

1997 - 2000 Faculty of Science, National University of Singapore, Singapore 

1996 - 1997 Faculty of Chemistry, University of Trieste, Trieste, Italy

1995 - 1996 Researcher at Poly-Bios, AREA Science Park, Trieste, Italy

1995 Graduate School and University Center, City University of New York, New York, NY, USA 

1993 - 1994 National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

1993 Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innsbruck, Austria 

1991 - 1992 International Centre for Science and High Technology, UNIDO, AREA Science Park, Trieste, Italy

1989 - 1991 Mount Sinai School of Medicine, City University of New York, New York, NY, USA

Specialization

Main field

Main interests of Prof. Frecer include computer-assisted combinatorial chemistry and molecular design, computational chemistry, physical, medicinal and polymer chemistry. During last two decades he was involved in molecular design of bioactive compounds with potential antiviral and antibacterial effects

Other fields

Expertise in protease inhibitor design, ligand-receptor interactions, homology protein modeling, molecular dynamics and ligand docking studies, electrostatic interactions in macromolecules, continuum and discrete models of solvation, modeling of small molecules and macromolecules, structure-based molecular design, elucidation of molecular mechanism of action, quantitative structure-activity relationships, ab initio quantum chemistry, and others.

Honors, Awards, Fellowships, Membership of Professional Societies

Slovak Chemical Society

Slovak Biophysical Society

Slovak Pharmaceutical Society

European Association for Cancer Research

Publications (list of selected recent publications)

  1. Allangba, K.N.P.G., Keita, M., Kre N´Guessan, R., Megnassan, E., Frecer, V., Miertuš, S. Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone-chalcone and isatin-chalcone inhibitors probing the S2 active site pocket. Journal of Enzyme Inhibition and Medicinal Chemistry 34(1), 547-561 (2019)
  2. Kollar, J., Frecer, V. How accurate is description of ligand - protein interactions by hybrid QM/MM approach? Journal of Molecular Modeling 24(1), 11 (2018)
  3. Kollar, J., Frecer, V. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatotrial approach and QM/MM calculations. Journal of Molecular Graphics and Modelling 48, 97-110 (2018)
  4. Kollar, J., Frecer, V. How accurate is the description of ligand-protein interations by a hybrid QM/MM approach? Journal of Molecular Modeling 24(1), No. 11 (2018)
  5. Hajzer, V., Fišera, R., Latika, A., Durmis, J., Kollár, J., Frecer, V., Tučeková, Z., Miertuš, S., Kostolanský, F., Varečková, E., Šebesta, R.: Stereoisomers of oseltamivir - synthesis, in silico prediction and biological evaluation. Org. Biomol. Chem. 15(8), 1828-1841 (2017).
  6. Svetlik, J., Pronayova, N., Frecer, V., Ciez, D.: Three-component reaction and organocatalysis in one: synthesis of densely substituted 4-aminochromanes. Tetrahedron 72(47), 7620-7627 (2016).
  7. Kouassi AF, Kone M, Keita M, Esmel A, Megnassan E, N'Guessan YT, Frecer V, Miertuš S.: Computer-aided design of orally bioavailable pyrrolidine carboxamide inhibitors of enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis with favorable pharmacokinetic profiles. Int. J. Mol. Sci. 16(12), 29744-29771 (2015).
  8. Owono Owono, L. C., Ntie-Kang, F., Keita, M., Megnassan, E., Frecer, V., Miertuš, S.: Virtually designed triclosan-based inhibitors of enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis and of Plasmodium falciparum. Mol. Inform. 34(5), 292-307 (2015).
  9. Kollar J., Frecer, V.: Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer. Curr. Pharm. Des. 21(11), 1472-1502 (2015).
  10. Svetlik, J., Pronayova, N., Svorc, L., Frecer, V.: A complicated path of salicylaldehyde through the Biginelli reaction: a case of unexpected spiroketalization. Tetrahedron 70(44), 8354-8360 (2014).
  11. Udommaneethanakit T., Rungrotmongkol T., Frecer V., Seneci P., Miertus S., Bren U.: Drugs against avian influenza A virus: Design of novel sulfonate inhibitors of neuraminidase N1. Curr. Pharm. Des. 20(21), 3478-3487 (2014).
  12. Berti F., Frecer V., Miertuš S.: Inhibitors of HIV-protease from computational design. A history of theory and synthesis still to be fully appreciated. Curr. Pharm. Des. 20(21), 3398-3411 (2014).
  13. Toti, K. S., Verbeke, F., Risseeuw, M. D. P., Frecer, V., Munier-Lehmann, H., Van Calenbergh, S.: Synthesis and evaluation of 5'-modified thymidines and 5-hydroxymethyl-2'-deoxyuridines as M. tuberculosis thymidylate kinase inhibitors. Bioorgan. Med. Chem. 21(1), 257-268 (2013).
  14. Dali, B., Keita, M., Megnassan, E., Frecer, V., Miertuš, S.: Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D. Chem. Biol. Drug Des. 79(4), 411-430 (2012).










Scopus